Additionally, subclinical doses of platinum-based drugs, such as cisplatin, prevented the generation and suppressive activity of M-MDSCs by inhibiting STAT3-COX2 signaling pathway, along with decreasing COX2 and arginase1 expression in M-MDSCs of melanoma and head and neck squamous cell carcinoma (HNSCC) patients (128). Here, PTGS2 is linked to melanoma.